Johnson & Johnson said it sold $502 million of its coronavirus vaccine in the third quarter, in its third-quarter financial statements that beat Wall Street earnings expectations.
The company reported adjusted earnings per share of $2.60 per share, versus expectations of $2.35 per share.
The company’s revenue came to $23.34 billion, versus expectations of $23.72 billion.
J&J raised its full-year earnings forecast to between $9.77 per share and $9.82 per share, from its previous estimate of $9.60 to $9.70 per share.
The company expects sales to range from $94.1 billion to $94.6 billion, up from a previous forecast of $93.8 billion to $94.6 billion.